Author: Ravi Shankar

• Production of high-performance recycled polyester T-shirts enabled by Carbios’ technology
• Full validation across the textile value chain, from pre-industrial recycling to industrial-scale manufacturing
• Identical performance between EnzyTex¹ recycled polyester and virgin polyester
• Three years of collaboration demonstrating the performance of fiber-to-fiber enzymatic recycling at scale

Clermont-Ferrand (France), 29 September 2026 (7:45 am CEST). Carbios (Euronext Growth Paris: ALCRB) announces the successful production of high-quality recycled polyester T-shirts made from complex textile and plastic waste² on European industrial manufacturing lines, in collaboration with the Fiber-to-Fiber Consortium members: Patagonia, PUMA and Salomon.

This achievement demonstrates the ability of Carbios’ biorecycling technology to transform complex waste streams into high-performance textile products meeting the requirements of every stage of industrial processing.

A EUROPEAN ACHIEVEMENT TO SERVE A GLOBAL TEXTILE INDUSTRY

This achievement is the result of close collaboration between Carbios, the members of the Fiber-to-Fiber Consortium, and European industrial partners spanning the entire textile value chain, from polymerization and spinning to knitting, dyeing, and garment manufacturing.

From complex feedstock to finished garment:

Starting from textile waste³ and complex plastic waste, the Carbios process enabled the production of monomers that meet stringent quality and performance standards, comparable to those of petrochemical-derived materials.

These monomers were then repolymerized by Selenis in Portugal to produce more than one ton of high-quality r-PET, marketed under the name EnzyTex, and designed for seamless integration into existing industrial production lines.

The resulting r-PET was converted into yarn on ANTEX’s industrial production lines in Spain, then knitted into Interlock fabric on Henitex’s industrial equipment in France, dyed in an industrial bath by TAD (Teintures et Apprêts Danjoux) in France, and finally turned into garments by ToptexCube (Chamatex Group) in France, with each step carried out under standard industrial conditions.

The resulting fibers demonstrated full compatibility with conventional textile manufacturing processes, while delivering performance characteristics, including mechanical strength, dyeability, and color fastness, equivalent to those of virgin polyester.

Manufactured entirely in Europe, this garment demonstrates the scalability of circular textile manufacturing without compromising on quality.

Benoît Grenot, CEO of Carbios: “This achievement demonstrates that enzymatic recycling meets the highest standards of the textile industry. By converting complex waste streams into high-purity building blocks for the production of recycled polyester, we are proving that circularity is already an operational reality ready for deployment at industrial scale.”

Howard Williams, Director Global Innovation Apparel & Accessories at PUMA: “Carbios has demonstrated that complex PET waste can be recycled into high-quality polyester fibers under existing industrial conditions and repurposed into high-quality products.”

Guillaume Meyzenq, CEO of Salomon: “The success of this Consortium highlights the power of collective intelligence to tackle one of our industry’s most complex challenges. By combining our expertise across the entire value chain, we have demonstrated that circularity for high-performance textiles is becoming an industrial reality. Together, we have proven that innovative recycling technologies can transform complex waste into high-quality materials without ever compromising on technical performance. For Salomon, this milestone opens significant opportunities to scale circular solutions and shape a more responsible future for outdoor sports apparel.”

A CONSORTIUM PUSHING THE BOUNDARIES OF TEXTILE CIRCULARITY

Initiated by Carbios, the Fiber-to-Fiber Consortium has enabled major progress:

• Validation of enzymatic recycling on complex textile waste streams, including blended and contaminated materials;
• Demonstration that EnzyTex recycled polyester matches the performance of its fossil-based counterpart;
• Confirmation of the industrial scalability of the Carbios process through the production of 100% recycled polyester products under standard operating conditions;
• European value chain integration.

Beyond the technical performance, Carbios and its partners have demonstrated that high-quality garments can be produced from complex waste streams and that circularity can be achieved without compromising performance.

###

About Carbios
Carbios is a biotechnology company that develops and industrializes biological solutions to reinvent the lifecycle of plastics and textiles. Inspired by nature, Carbios designs enzyme-based biological processes to break down plastics, with the mission of preventing plastic and textile pollution and accelerating the transition to a circular economy. Its two innovative technologies—dedicated to PET biorecycling and PLA biodegradation—are currently scaling up to industrial and commercial levels. Carbios is supported by prestigious brands in the cosmetics, food, and apparel industries, aiming to improve the recyclability and circularity of their products. Nestlé Waters, PepsiCo, and Suntory Beverage & Food Europe took part in a packaging consortium founded by Carbios and L’Oréal. On, Patagonia, PUMA, PVH Corp., and Salomon collaborate with Carbios in a textile consortium. Carbios is part of the global community of B Corp™ certified companies that are transforming their business models to serve the common good.

Visit www.carbios.com to learn more about biotechnology for circular plastics and textiles.
LinkedIn : carbios / Instagram : carbios

Information on Carbios shares:

ISIN Code FR0011648716 
Ticker Code Euronext Growth: ALCRB 
LEI 969500M2RCIWO4NO5F08 

Carbios is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.

About Patagonia

We’re in business to save our home planet. Founded by Yvon Chouinard in 1973, Patagonia is an outdoor apparel company based in Ventura, California. As a certified B Corporation and a founding member of 1% for the Planet, the company is recognized internationally for its product quality and environmental activism, as well as its contributions of more than $230 million to environmental organizations. Its unique ownership structure reflects that Earth is its only shareholder: Profits not reinvested back into the business are paid as dividends to protect the planet.

About PUMA

PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 70 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 16,000 people worldwide, and is headquartered in Herzogenaurach, Germany.

About Salomon

Salomon is the modern mountain sport lifestyle brand creating innovative, premium and authentic footwear, apparel and winter sports equipment in the French Alps. We’re more than innovators, we’re futurists. We don’t predict trends, we shape the future. At the Annecy Design Center, designers, engineers and athletes intersect to explore the white space of tomorrow and create the future of sports and culture.

Disclaimer on forward-looking statements and risk factors:
This press release contains forward-looking statements, not historical data, and should not be construed as a guarantee that the facts and data stated will occur. These forward-looking statements are based on data, assumptions and estimates considered reasonable by Carbios. Carbios operates in a competitive and rapidly evolving environment. It is therefore not in a position to anticipate all risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of a risk or combination of risks could lead to results that differ significantly from those mentioned in any forward-looking statement. Carbios draws your attention to the fact that forward-looking statements are in no way a guarantee of its future performance and that its actual financial position, results, cash flows, its partnerships and corporate agreements, and the development of the sector in which Carbios operates may differ significantly from those proposed or suggested by the forward-looking statements contained in this document. In addition, even if Carbios’ financial position, results, cash flows, its partnerships and corporate agreements, and developments in the industry in which it operates are consistent with the forward-looking information contained in this document, such results or developments may not be a reliable indication of Carbios’ future results or developments. Readers are also advised to carefully consider the risk factors described in the Universal registration document filed with the French Market Authority (“AMF”) and available free of charge on the Company’s website. Should all or any part of these risk factors occur or others, in no case whatsoever will Carbios be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages. This information is given only as of the date of this press release. Carbios makes no commitment to publish updates to this information or on the assumptions on which it is based, except in accordance with any legal or regulatory obligation applicable to it.

For additional information, please contact:

Carbios Laura Perrin Communications contact@carbios.com +33 (0)4 73 86 51 76

Carbios Benjamin Audebert Investor Relations contact@carbios.com +33 (0)4 73 86 51 76

Maarc – Relations Presse Bruno Arabian bruno.arabian@maarc.fr +33 (0)6 87 88 47 26 Simon Dulucq Simon.dulucq@maarc.fr +33 (0) 6 10 98 55 64

---

1 Available as textile-grade r-PET pellets or yarn, EnzyTex is a high-purity recycled material produced using Carbios’ biorecycling technology and designed for seamless integration into existing textile production lines.
2 These materials are considered difficult to recycle due to fiber blends (cotton, elastane) and contaminants (dyes, finishes, silicones).
3 Pre-industrial and post-consumer textiles.

Attachment

• 2026 09 29 – PR Carbios – Textile Consortium

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.
THIS PRESS RELEASE IS AN ADVERTISEMENT AND NOT A PROSPECTUS WITHIN THE MEANING OF REGULATION (EU) 2017/1129 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 14 JUNE 2017, AS AMENDED.
THIS PRESS RELEASE IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES.

Rexel announces the success of its c. €500 million Capital Increase, without shareholders’ preferential subscription right, to partially fund the acquisition of GCG

Rexel announces today the success of its share capital increase of approximately 500 million euros by means of an issue of new shares without shareholders’ preferential subscription right via an accelerated bookbuilding The net proceeds from the capital increase will be used to partially finance the acquisition of GCG, as previously announced in the company’s press release dated 25 September 2026

Paris, September 29, 2026

Rexel (the “Company”) has successfully placed 14,388,490 new shares (the “New Shares”, representing c. 4.6% of the share capital of the Company prior to the issue) in an offering by way of an accelerated bookbuilding. The New Shares will be issued in a capital increase without shareholders’ preferential subscription rights (the “Capital Increase”) at a price of EUR 34.75 per share resulting in gross proceeds of approximately 500 million euros before deduction of commissions and expenses.

The subscription price is set at €34.75 per New Share (including €5.00 of par value and €29.75 of issue premium), representing a discount of c. 1.0% on the last closing price prior to the announcement of the launch of the Capital Increase on 28 September 2026.

Use of proceeds

The net proceeds from the Capital Increase will be used to partially finance the acquisition of GCG (the “Acquisition”) and will contribute to preserving Rexel’s credit rating and maintaining a net financial debt / EBITDAaL ratio of approximately 2.0x from 2027, in line with its guidance, thereby strengthening its financial flexibility and capacity to capture the multiple growth opportunities ahead.

The Capital Increase represents the equity component of the Acquisition’s financing structure which would also encompass a mix of cash on hand and debt. For further details on the Acquisition and its funding, please see the Company’s announcement of September 25, 2026.

Key terms and indicative timetable of the Capital Increase

The Capital Increase has been carried out without shareholders’ preferential subscription right nor priority subscription period pursuant to the authorization granted by the Company’s annual shareholders’ general meeting held on 29 April 2025 (18^th resolution) and in accordance with the provisions of Article L.411-2 1° of the French Code monétaire et financier, in France and outside France with no public offering in any jurisdiction (including France) other than to qualified investors (as defined in Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”)). The New Shares have been offered for subscription in a private placement by way of an accelerated bookbuilding process exclusively to qualified investors as defined in the Prospectus Regulation.

The New Shares will bear current dividend rights and will be immediately assimilated with the Company’s existing shares. The New Shares will trade under the same ISIN code as the Company’s existing shares, FR0010451203, on the regulated market of Euronext in Paris.

Settlement and delivery of the Capital Increase is expected to take place on or around October 1, 2026.

Lock-up undertaking

In the context of the Capital Increase, the Company has agreed to a lock-up undertaking with respect to the issuance or sale of shares and securities giving access to the share capital for a period ending 90 calendar days after the settlement, subject to certain customary exceptions and waiver by the Joint Global Coordinators.

Dilution

For illustrative purposes only, a shareholder holding 1% of the Company’s share capital⁽¹⁾ as of September 28, 2026, and not subscribing to the Capital Increase, would hold c. 0.96%, on a non-diluted basis (c. 0.93%, on a diluted basis), of the Company’s share capital⁽¹⁾ following the issue of the New Shares.

Financial intermediaries

BofA Securities, BNP PARIBAS and Crédit Agricole Corporate and Investment Bank acted as Joint Global Coordinators and Joint Bookrunners in the Capital Increase, and Jefferies GmbH, Natixis and Société Générale acted as Joint Bookrunners. Rothschild & Co is acting as independent financial advisor to Rexel.

Public information & Risk factors

Neither the offer of the New Shares nor their admission to trading on the regulated market of Euronext Paris is subject to a prospectus requiring an approval by the French financial market authority (Autorité des marchés financiers) (the “AMF”).

Detailed information on the Company, including its business, results, perspectives and related risk factors to which the Company is exposed, are described in the Company’s universal registration document for the financial year ended 31 December 2025, filed by the Company with the AMF under No. D.26-0073 on 10 March 2026, and in the Company’s half-year financial report for the period ended on 30 June 2026 dated 27 July 2026. The Company’s press release relating to the Acquisition and the related presentation, together with the Company’s other press releases and regulated information concerning Rexel are all available on the Company’s website (www.rexel.com/en/investors-analysts).

The realization of all or part of these risks factors may have an adverse effect on the activities, the financial situation, the results, the development, or the perspectives of the Company.

In addition, investors are invited to take into account the risks that are specific to the Capital Increase as follows:

• the market price of the Company’s shares could fluctuate and fall below the subscription price of the shares issued in connection with the Capital Increase,
• the volatility and liquidity of the Company’s shares could fluctuate significantly,
• sales of the Company’s shares could occur on the market and have an adverse impact on the Company’s share price, and
• the Company’s shareholders could suffer additional dilution in the event of future transactions.

Furthermore, the Acquisition is subject to various conditions precedent. If the necessary authorisations and approvals are not obtained within the envisaged timeframes, the Acquisition may not be completed according to the anticipated timetable by the end of 2026, or may not be completed at all. The expected benefits of the Acquisition may not materialise within the anticipated timeframe. The Company may also be exposed to liabilities and risks of which it was unaware or which had not been properly assessed at the time of the transaction, which could adversely affect its operations and results.

Furthermore, the transactions involved in the refinancing of the Acquisition may not be completed within the anticipated timeframe or may not be completed at all, may result in an increase in the Company’s expenses and liabilities under unforeseen circumstances, and/or may expose the Company to impairment losses and amortisation on goodwill and other intangible assets.

About Rexel Group

Rexel, worldwide expert in the multichannel professional distribution of products and services for the energy world, addresses three main markets: residential, non-residential, and industrial. The Group supports its residential, non-residential, and industrial customers by providing a tailored and scalable range of products and services in energy management for construction, renovation, production, and maintenance. Rexel operates through a network of 1,876 branches in 17 countries, with 26,306 employees. The Group’s sales were €19.4 billion in 2025.

Rexel is listed on the regulated market of Euronext Paris (compartment A, ticker RXL, ISIN code FR0010451203). It is included in the following indices: MSCI World, CAC Next 20, SBF 120, CAC Large 60, CAC SBT 1.5 NR, CAC AllTrade, CAC AllShares, FTSE EuroMid, and STOXX600. Rexel is also part of the following SRI indices: FTSE4Good, Dow Jones Sustainability Index Europe, Euronext Sustainable Europe 120 and S&P Global Sustainability Yearbook 2025, in recognition of its performance in terms of Corporate Social Responsibility (CSR).

For more information, visit www.rexel.com/en.

CONTACTS

FINANCIAL ANALYSTS/INVESTORS

Ludovic DEBAILLEUX

+33 1 42 85 76 12

ludovic.debailleux@rexel.com

PRESS

Taddeo: Pierre-Jean Lemauff

+33 7 77 78 58 67

pierre-jean.lemauff@taddeo.fr

Forward-looking statements

This press release includes forward‑looking statements. These forward‑looking statements include, but are not limited to, statements relating to the acquisition of GCG by the Company (including the anticipated benefits, results, effects and timing of the transaction), all statements regarding the expected future financial condition of the Company (and of GCG when combined with the Company), operating results, cash flows, dividends, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities, synergies, management plans and objectives, and statements containing terms such as “anticipate”, “approximate”, “believe”, “expect”, “estimate”, “forecast”, “intend”, “may”, “might”, “project”, “should”, “potential”, “advantage”, and similar expressions. Statements in this press release relating to future business prospects or anticipated financial or economic performance, profitability, revenues, expenses, dividends or other financial metrics of the Company (and of the combined activities of the Company and GCG), as well as other statements that are not historical facts, are forward‑looking statements that represent estimates made by the Company on the basis of information currently available. Forward‑looking statements are, by their nature, subject to significant business, economic and competitive risks, uncertainties and contingencies, many of which are unknown and many of which cannot be anticipated or controlled by the Company or GCG. These factors may cause the Company’s actual results, performance or plans relating to GCG to differ materially from those expressed or implied in such forward‑looking statements. Such risks and uncertainties include, without limitation, the risk factors discussed or identified in the public documents filed or to be filed by the Company with the AMF from time to time. Any forward‑looking statements made by the Company are made as of the date of this press release and do not constitute a guarantee of future performance.

The information contained in this press release is indicative and may be subject to significant updating, revision or amendment. This press release contains only summary information and should not be regarded as comprehensive.

Neither the Company, nor any of the members of the bank syndicate undertakes to update, amend or complete the information contained in this press release in order to reflect new information, new events or for any other reason, and the information contained in this press release may be modified without prior notification, subject to applicable legal and regulatory requirements.

IMPORTANT NOTICE

This press release may not be released, published or distributed, directly or indirectly, in or into the United States of America, Canada, Australia, Japan or South Africa. The distribution of this press release may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes, should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This press release does not constitute or form part of any offer or solicitation to purchase or subscribe for or to sell new shares to any person in the United States of America, Canada (with the exception of the provinces of Alberta, British Columbia, Ontario, Quebec and Manitoba), Australia, Japan or South Africa or in any jurisdiction to whom or in which such offer is unlawful, and the offering of the new shares is not an offer to the public in any jurisdiction including France, other than to qualified investors within the meaning of the Prospectus Regulation, or an offer to retail investors.

No communication or information relating to the offering of the new shares may be transmitted to the public in a country where there is a registration obligation or where an approval is required. No action has been or will be taken in any country in which such registration or approval would be required. The issuance or the subscription of the new shares may be subject to legal and regulatory restrictions in certain jurisdictions; neither the Company nor the Joint Bookrunners assume any liability in connection with any violation by any person of such restrictions.

This press release is an advertisement and not a prospectus within the meaning of the Prospectus Regulation. This press release is not an offer to the public other than to qualified investors, nor an offer to subscribe or a solicitation for the purposes of an offer to the public other than to qualified investors in any jurisdiction, including France.

The new shares referred to herein may not be offered or sold in the United States (including its territories and dependencies, any state of the United States and the District of Columbia). This press release does not constitute an offer or a solicitation of an offer of securities in the United States. The offer and sale of new shares described in this press release have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or the securities laws of any state or other jurisdiction of the United States, and such securities may not be offered, sold, pledged or otherwise transferred in the United States absent registration under the U.S. Securities Act or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements thereof and applicable state or local securities laws. The Company does not intend to make a public offer of its securities in the United States

The offering of the new shares in Canada is being made on a private placement basis only in the provinces of Alberta, British Columbia, Ontario Québec and Manitoba pursuant to an exemption from the prospectus requirements of applicable Canadian securities laws. No prospectus has been or will be filed with any securities commission or other securities regulatory authority in any jurisdiction in Canada in connection with the offer or sale of the new shares. In Canada, the new shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations.

The offer and sale of new shares referred to herein have not been and will not be registered under the U.S. Securities Act or under the applicable securities laws of Canada, Australia, Japan or South Africa. Subject to certain exceptions, the new shares referred to herein may not be offered or sold in Canada, Australia, Japan or South Africa or to, or for the account or benefit of, any national, resident or citizen of such countries. There will be no public offer of the new shares in the United States of America, Canada, Australia, Japan or South Africa or elsewhere.

In member states of the European Economic Area (the “EEA”), this announcement and any offer if made subsequently is directed exclusively at persons who are “qualified investors” within the meaning of the Prospectus Regulation (“Qualified Investors”).

In the United Kingdom, the distribution of this announcement and any offer if made subsequently is directed exclusively at persons who are “qualified investors” within the meaning of paragraph 15 of Schedule 1 of the Public Offers and Admissions to Trading Regulations 2024, (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (ii) who fall within Article 49(2)(A) to (D) of the Order, or (iii) to whom it may otherwise lawfully be communicated (all such persons together with Qualified Investors in the EEA being referred to herein as “Relevant Persons”). This press release is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this press release relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

Each of the Joint Bookrunners is acting exclusively for the Company and no-one else in connection with the Capital Increase. They will not regard any other person as their respective clients in relation to the Capital Increase and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, nor for providing advice in relation to the Capital Increase, the content of this announcement or any transaction, arrangement or other matter referred to herein.

In connection with the Capital Increase, the Joint Bookrunners and any of their respective affiliates may take up a portion of the new shares as a principal position and in that capacity may retain, purchase, sell, offer to sell for their own accounts such new shares and other securities of the Company or related investments in connection with the Capital Increase or otherwise. Accordingly, references to the new shares being issued, offered, subscribed, acquired, placed or otherwise dealt in should be read as including any issue or offer to, or subscription, acquisition, placing or dealing by, the Joint Bookrunners and any of their respective affiliates acting in such capacity. In addition, the Joint Bookrunners and any of their respective affiliates may enter into financing arrangements (including swaps, warrants or contracts for differences) with investors in connection with which the Joint Bookrunners and any of their respective affiliates may from time to time acquire, hold or dispose of new shares. The Joint Bookrunners do not intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so.

A communication that a transaction is or that the book is “covered” (i.e. indicated demand from investors in the book equals or exceeds the amount of the new shares being offered) is not any indication or assurance that the book will remain covered or that the transaction and new shares will be fully distributed by the Joint Bookrunners. The Joint Bookrunners reserve the right to take up a portion of the new shares in the Capital Increase as a principal position at any stage at their sole discretion, inter alia, to take account of the objectives of the Company, MiFID II requirements and in accordance with allocation policies.

None of the Joint Bookrunners or any of their respective directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith.

Each distributor is responsible for undertaking its own target market assessment in respect of the securities and determining appropriate distribution channels.

---

⁽¹⁾ Comprised of 296,997,254 ordinary shares as at 28 September 2026 (including treasury shares).

Attachment

• Rexel – Augmentation de capital – Resultats – UK

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.
THIS PRESS RELEASE IS AN ADVERTISEMENT AND NOT A PROSPECTUS WITHIN THE MEANING OF REGULATION (EU) 2017/1129 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 14 JUNE 2017, AS AMENDED.
THIS PRESS RELEASE IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES.

Rexel announces the success of its c. €500 million Capital Increase, without shareholders’ preferential subscription right, to partially fund the acquisition of GCG

Rexel announces today the success of its share capital increase of approximately 500 million euros by means of an issue of new shares without shareholders’ preferential subscription right via an accelerated bookbuilding The net proceeds from the capital increase will be used to partially finance the acquisition of GCG, as previously announced in the company’s press release dated 25 September 2026

Paris, September 29, 2026

Rexel (the “Company”) has successfully placed 14,388,490 new shares (the “New Shares”, representing c. 4.6% of the share capital of the Company prior to the issue) in an offering by way of an accelerated bookbuilding. The New Shares will be issued in a capital increase without shareholders’ preferential subscription rights (the “Capital Increase”) at a price of EUR 34.75 per share resulting in gross proceeds of approximately 500 million euros before deduction of commissions and expenses.

The subscription price is set at €34.75 per New Share (including €5.00 of par value and €29.75 of issue premium), representing a discount of c. 1.0% on the last closing price prior to the announcement of the launch of the Capital Increase on 28 September 2026.

Use of proceeds

The net proceeds from the Capital Increase will be used to partially finance the acquisition of GCG (the “Acquisition”) and will contribute to preserving Rexel’s credit rating and maintaining a net financial debt / EBITDAaL ratio of approximately 2.0x from 2027, in line with its guidance, thereby strengthening its financial flexibility and capacity to capture the multiple growth opportunities ahead.

The Capital Increase represents the equity component of the Acquisition’s financing structure which would also encompass a mix of cash on hand and debt. For further details on the Acquisition and its funding, please see the Company’s announcement of September 25, 2026.

Key terms and indicative timetable of the Capital Increase

The Capital Increase has been carried out without shareholders’ preferential subscription right nor priority subscription period pursuant to the authorization granted by the Company’s annual shareholders’ general meeting held on 29 April 2025 (18^th resolution) and in accordance with the provisions of Article L.411-2 1° of the French Code monétaire et financier, in France and outside France with no public offering in any jurisdiction (including France) other than to qualified investors (as defined in Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”)). The New Shares have been offered for subscription in a private placement by way of an accelerated bookbuilding process exclusively to qualified investors as defined in the Prospectus Regulation.

The New Shares will bear current dividend rights and will be immediately assimilated with the Company’s existing shares. The New Shares will trade under the same ISIN code as the Company’s existing shares, FR0010451203, on the regulated market of Euronext in Paris.

Settlement and delivery of the Capital Increase is expected to take place on or around October 1, 2026.

Lock-up undertaking

In the context of the Capital Increase, the Company has agreed to a lock-up undertaking with respect to the issuance or sale of shares and securities giving access to the share capital for a period ending 90 calendar days after the settlement, subject to certain customary exceptions and waiver by the Joint Global Coordinators.

Dilution

For illustrative purposes only, a shareholder holding 1% of the Company’s share capital⁽¹⁾ as of September 28, 2026, and not subscribing to the Capital Increase, would hold c. 0.96%, on a non-diluted basis (c. 0.93%, on a diluted basis), of the Company’s share capital⁽¹⁾ following the issue of the New Shares.

Financial intermediaries

BofA Securities, BNP PARIBAS and Crédit Agricole Corporate and Investment Bank acted as Joint Global Coordinators and Joint Bookrunners in the Capital Increase, and Jefferies GmbH, Natixis and Société Générale acted as Joint Bookrunners. Rothschild & Co is acting as independent financial advisor to Rexel.

Public information & Risk factors

Neither the offer of the New Shares nor their admission to trading on the regulated market of Euronext Paris is subject to a prospectus requiring an approval by the French financial market authority (Autorité des marchés financiers) (the “AMF”).

Detailed information on the Company, including its business, results, perspectives and related risk factors to which the Company is exposed, are described in the Company’s universal registration document for the financial year ended 31 December 2025, filed by the Company with the AMF under No. D.26-0073 on 10 March 2026, and in the Company’s half-year financial report for the period ended on 30 June 2026 dated 27 July 2026. The Company’s press release relating to the Acquisition and the related presentation, together with the Company’s other press releases and regulated information concerning Rexel are all available on the Company’s website (www.rexel.com/en/investors-analysts).

The realization of all or part of these risks factors may have an adverse effect on the activities, the financial situation, the results, the development, or the perspectives of the Company.

In addition, investors are invited to take into account the risks that are specific to the Capital Increase as follows:

• the market price of the Company’s shares could fluctuate and fall below the subscription price of the shares issued in connection with the Capital Increase,
• the volatility and liquidity of the Company’s shares could fluctuate significantly,
• sales of the Company’s shares could occur on the market and have an adverse impact on the Company’s share price, and
• the Company’s shareholders could suffer additional dilution in the event of future transactions.

Furthermore, the Acquisition is subject to various conditions precedent. If the necessary authorisations and approvals are not obtained within the envisaged timeframes, the Acquisition may not be completed according to the anticipated timetable by the end of 2026, or may not be completed at all. The expected benefits of the Acquisition may not materialise within the anticipated timeframe. The Company may also be exposed to liabilities and risks of which it was unaware or which had not been properly assessed at the time of the transaction, which could adversely affect its operations and results.

Furthermore, the transactions involved in the refinancing of the Acquisition may not be completed within the anticipated timeframe or may not be completed at all, may result in an increase in the Company’s expenses and liabilities under unforeseen circumstances, and/or may expose the Company to impairment losses and amortisation on goodwill and other intangible assets.

About Rexel Group

Rexel, worldwide expert in the multichannel professional distribution of products and services for the energy world, addresses three main markets: residential, non-residential, and industrial. The Group supports its residential, non-residential, and industrial customers by providing a tailored and scalable range of products and services in energy management for construction, renovation, production, and maintenance. Rexel operates through a network of 1,876 branches in 17 countries, with 26,306 employees. The Group’s sales were €19.4 billion in 2025.

Rexel is listed on the regulated market of Euronext Paris (compartment A, ticker RXL, ISIN code FR0010451203). It is included in the following indices: MSCI World, CAC Next 20, SBF 120, CAC Large 60, CAC SBT 1.5 NR, CAC AllTrade, CAC AllShares, FTSE EuroMid, and STOXX600. Rexel is also part of the following SRI indices: FTSE4Good, Dow Jones Sustainability Index Europe, Euronext Sustainable Europe 120 and S&P Global Sustainability Yearbook 2025, in recognition of its performance in terms of Corporate Social Responsibility (CSR).

For more information, visit www.rexel.com/en.

CONTACTS

FINANCIAL ANALYSTS/INVESTORS

Ludovic DEBAILLEUX

+33 1 42 85 76 12

ludovic.debailleux@rexel.com

PRESS

Taddeo: Pierre-Jean Lemauff

+33 7 77 78 58 67

pierre-jean.lemauff@taddeo.fr

Forward-looking statements

This press release includes forward‑looking statements. These forward‑looking statements include, but are not limited to, statements relating to the acquisition of GCG by the Company (including the anticipated benefits, results, effects and timing of the transaction), all statements regarding the expected future financial condition of the Company (and of GCG when combined with the Company), operating results, cash flows, dividends, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities, synergies, management plans and objectives, and statements containing terms such as “anticipate”, “approximate”, “believe”, “expect”, “estimate”, “forecast”, “intend”, “may”, “might”, “project”, “should”, “potential”, “advantage”, and similar expressions. Statements in this press release relating to future business prospects or anticipated financial or economic performance, profitability, revenues, expenses, dividends or other financial metrics of the Company (and of the combined activities of the Company and GCG), as well as other statements that are not historical facts, are forward‑looking statements that represent estimates made by the Company on the basis of information currently available. Forward‑looking statements are, by their nature, subject to significant business, economic and competitive risks, uncertainties and contingencies, many of which are unknown and many of which cannot be anticipated or controlled by the Company or GCG. These factors may cause the Company’s actual results, performance or plans relating to GCG to differ materially from those expressed or implied in such forward‑looking statements. Such risks and uncertainties include, without limitation, the risk factors discussed or identified in the public documents filed or to be filed by the Company with the AMF from time to time. Any forward‑looking statements made by the Company are made as of the date of this press release and do not constitute a guarantee of future performance.

The information contained in this press release is indicative and may be subject to significant updating, revision or amendment. This press release contains only summary information and should not be regarded as comprehensive.

Neither the Company, nor any of the members of the bank syndicate undertakes to update, amend or complete the information contained in this press release in order to reflect new information, new events or for any other reason, and the information contained in this press release may be modified without prior notification, subject to applicable legal and regulatory requirements.

IMPORTANT NOTICE

This press release may not be released, published or distributed, directly or indirectly, in or into the United States of America, Canada, Australia, Japan or South Africa. The distribution of this press release may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes, should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This press release does not constitute or form part of any offer or solicitation to purchase or subscribe for or to sell new shares to any person in the United States of America, Canada (with the exception of the provinces of Alberta, British Columbia, Ontario, Quebec and Manitoba), Australia, Japan or South Africa or in any jurisdiction to whom or in which such offer is unlawful, and the offering of the new shares is not an offer to the public in any jurisdiction including France, other than to qualified investors within the meaning of the Prospectus Regulation, or an offer to retail investors.

No communication or information relating to the offering of the new shares may be transmitted to the public in a country where there is a registration obligation or where an approval is required. No action has been or will be taken in any country in which such registration or approval would be required. The issuance or the subscription of the new shares may be subject to legal and regulatory restrictions in certain jurisdictions; neither the Company nor the Joint Bookrunners assume any liability in connection with any violation by any person of such restrictions.

This press release is an advertisement and not a prospectus within the meaning of the Prospectus Regulation. This press release is not an offer to the public other than to qualified investors, nor an offer to subscribe or a solicitation for the purposes of an offer to the public other than to qualified investors in any jurisdiction, including France.

The new shares referred to herein may not be offered or sold in the United States (including its territories and dependencies, any state of the United States and the District of Columbia). This press release does not constitute an offer or a solicitation of an offer of securities in the United States. The offer and sale of new shares described in this press release have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or the securities laws of any state or other jurisdiction of the United States, and such securities may not be offered, sold, pledged or otherwise transferred in the United States absent registration under the U.S. Securities Act or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements thereof and applicable state or local securities laws. The Company does not intend to make a public offer of its securities in the United States

The offering of the new shares in Canada is being made on a private placement basis only in the provinces of Alberta, British Columbia, Ontario Québec and Manitoba pursuant to an exemption from the prospectus requirements of applicable Canadian securities laws. No prospectus has been or will be filed with any securities commission or other securities regulatory authority in any jurisdiction in Canada in connection with the offer or sale of the new shares. In Canada, the new shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations.

The offer and sale of new shares referred to herein have not been and will not be registered under the U.S. Securities Act or under the applicable securities laws of Canada, Australia, Japan or South Africa. Subject to certain exceptions, the new shares referred to herein may not be offered or sold in Canada, Australia, Japan or South Africa or to, or for the account or benefit of, any national, resident or citizen of such countries. There will be no public offer of the new shares in the United States of America, Canada, Australia, Japan or South Africa or elsewhere.

In member states of the European Economic Area (the “EEA”), this announcement and any offer if made subsequently is directed exclusively at persons who are “qualified investors” within the meaning of the Prospectus Regulation (“Qualified Investors”).

In the United Kingdom, the distribution of this announcement and any offer if made subsequently is directed exclusively at persons who are “qualified investors” within the meaning of paragraph 15 of Schedule 1 of the Public Offers and Admissions to Trading Regulations 2024, (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (ii) who fall within Article 49(2)(A) to (D) of the Order, or (iii) to whom it may otherwise lawfully be communicated (all such persons together with Qualified Investors in the EEA being referred to herein as “Relevant Persons”). This press release is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this press release relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

Each of the Joint Bookrunners is acting exclusively for the Company and no-one else in connection with the Capital Increase. They will not regard any other person as their respective clients in relation to the Capital Increase and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, nor for providing advice in relation to the Capital Increase, the content of this announcement or any transaction, arrangement or other matter referred to herein.

In connection with the Capital Increase, the Joint Bookrunners and any of their respective affiliates may take up a portion of the new shares as a principal position and in that capacity may retain, purchase, sell, offer to sell for their own accounts such new shares and other securities of the Company or related investments in connection with the Capital Increase or otherwise. Accordingly, references to the new shares being issued, offered, subscribed, acquired, placed or otherwise dealt in should be read as including any issue or offer to, or subscription, acquisition, placing or dealing by, the Joint Bookrunners and any of their respective affiliates acting in such capacity. In addition, the Joint Bookrunners and any of their respective affiliates may enter into financing arrangements (including swaps, warrants or contracts for differences) with investors in connection with which the Joint Bookrunners and any of their respective affiliates may from time to time acquire, hold or dispose of new shares. The Joint Bookrunners do not intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so.

A communication that a transaction is or that the book is “covered” (i.e. indicated demand from investors in the book equals or exceeds the amount of the new shares being offered) is not any indication or assurance that the book will remain covered or that the transaction and new shares will be fully distributed by the Joint Bookrunners. The Joint Bookrunners reserve the right to take up a portion of the new shares in the Capital Increase as a principal position at any stage at their sole discretion, inter alia, to take account of the objectives of the Company, MiFID II requirements and in accordance with allocation policies.

None of the Joint Bookrunners or any of their respective directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith.

Each distributor is responsible for undertaking its own target market assessment in respect of the securities and determining appropriate distribution channels.

---

⁽¹⁾ Comprised of 296,997,254 ordinary shares as at 28 September 2026 (including treasury shares).

Attachment

• Rexel – Augmentation de capital – Resultats – UK

Technip Energies (PARIS:TE) has been awarded contracts by Petkim, a subsidiary of SOCAR, in connection with the development of a proposed integrated petrochemical complex in Aliağa, Türkiye. 

The contracts include the license for a world-scale mixed-feed ethylene cracking unit, as well as the integrated Process Design Package (PDP) and Front-End Engineering Design (FEED) services for the overall complex.

The FEED scope covers the steam cracker designed with an ethylene production capacity of approximately 1,200 KTA¹ and a propylene production capacity of 550 KTA, together with an 850 KTA HDPE/LLDPE complex (two 425 KTA trains) and a 550 KTA polypropylene plant integrated with the new cracker.

The awarded scope covers the licensing, PDP and FEED phases of the proposed project and constitutes an important step in its technical development prior to any Final Investment Decision (FID) by PETKIM.

The planned integrated petrochemical complex is intended to produce key petrochemical building blocks used to manufacture a wide range of everyday products, including packaging materials, consumer goods, automotive components and industrial applications.

Stéphane Mespoulhes, Senior Vice President Ethylene and Polyolefins at Technip Energies, commented: “We are pleased to support Petkim at this important stage in the development of its integrated petrochemical complex. By combining our ethylene technology with our engineering capabilities, we will support Petkim through the PDP and FEED phases as the project progresses through its technical development. This early engagement will help establish the technical foundations for an efficient, flexible and competitive project.”

This award was recorded in Q3 2026 in the Project Delivery and Technology, Products & Services segments.

 1. Kilotons per annum

About Technip Energies

Technip Energies is a global technology and engineering powerhouse. With leadership positions in LNG, hydrogen, ethylene, sustainable chemistry, and CO₂ management, we are contributing to the development of critical markets such as energy, energy derivatives, decarbonization, and circularity. Our complementary business segments, Technology, Products and Services (TPS) and Project Delivery, turn innovation into scalable and industrial reality.

Through collaboration and excellence in execution, our 18,000+ employees across 35 countries are fully committed to bridging prosperity with sustainability for a world designed to last.

Technip Energies generated revenues of €7.2 billion in 2025 and is listed on Euronext Paris. The Company also has American Depositary Receipts trading over the counter.

For further information: www.ten.com

Contacts

Investor Relations
Phillip Lindsay
Vice-President Investor Relations
Tel: +44 207 585 5051
Email: Phillip Lindsay

Media Relations
Jason Hyonne

Head of Press Relations & Social Media
Tel: +33 1 47 78 22 89
Email: Jason Hyonne

Attachments

• Technip Energies awarded engineering and technology contracts by Petkim
• Technip Energies awarded contrats by Petkim

Technip Energies (PARIS:TE) has been awarded contracts by Petkim, a subsidiary of SOCAR, in connection with the development of a proposed integrated petrochemical complex in Aliağa, Türkiye. 

The contracts include the license for a world-scale mixed-feed ethylene cracking unit, as well as the integrated Process Design Package (PDP) and Front-End Engineering Design (FEED) services for the overall complex.

The FEED scope covers the steam cracker designed with an ethylene production capacity of approximately 1,200 KTA¹ and a propylene production capacity of 550 KTA, together with an 850 KTA HDPE/LLDPE complex (two 425 KTA trains) and a 550 KTA polypropylene plant integrated with the new cracker.

The awarded scope covers the licensing, PDP and FEED phases of the proposed project and constitutes an important step in its technical development prior to any Final Investment Decision (FID) by PETKIM.

The planned integrated petrochemical complex is intended to produce key petrochemical building blocks used to manufacture a wide range of everyday products, including packaging materials, consumer goods, automotive components and industrial applications.

Stéphane Mespoulhes, Senior Vice President Ethylene and Polyolefins at Technip Energies, commented: “We are pleased to support Petkim at this important stage in the development of its integrated petrochemical complex. By combining our ethylene technology with our engineering capabilities, we will support Petkim through the PDP and FEED phases as the project progresses through its technical development. This early engagement will help establish the technical foundations for an efficient, flexible and competitive project.”

This award was recorded in Q3 2026 in the Project Delivery and Technology, Products & Services segments.

 1. Kilotons per annum

About Technip Energies

Technip Energies is a global technology and engineering powerhouse. With leadership positions in LNG, hydrogen, ethylene, sustainable chemistry, and CO₂ management, we are contributing to the development of critical markets such as energy, energy derivatives, decarbonization, and circularity. Our complementary business segments, Technology, Products and Services (TPS) and Project Delivery, turn innovation into scalable and industrial reality.

Through collaboration and excellence in execution, our 18,000+ employees across 35 countries are fully committed to bridging prosperity with sustainability for a world designed to last.

Technip Energies generated revenues of €7.2 billion in 2025 and is listed on Euronext Paris. The Company also has American Depositary Receipts trading over the counter.

For further information: www.ten.com

Contacts

Investor Relations
Phillip Lindsay
Vice-President Investor Relations
Tel: +44 207 585 5051
Email: Phillip Lindsay

Media Relations
Jason Hyonne

Head of Press Relations & Social Media
Tel: +33 1 47 78 22 89
Email: Jason Hyonne

Attachments

• Technip Energies awarded engineering and technology contracts by Petkim
• Technip Energies awarded contrats by Petkim

Leiden, the Netherlands, September 29, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Mr. Chouraqui will step down as Chief Executive Officer and Executive Director, with immediate effect.

To ensure continuity of leadership, the Board of Directors has appointed Mrs. Leverne Marsh, Chief Commercial Officer, and Mr. Kenneth Lynard, Chief Financial Officer, as Interim Co-CEOs, effective immediately. Mrs. Marsh will lead the patient-focused operations while Mr. Lynard will lead the global corporate functions. The Board has started a formal search for a permanent successor.

Following discussions about the execution of Pharming’s strategic priorities for the next phase of the company, the Board of Directors and Mr. Chouraqui have concluded that their views on how to advance the company’s strategy are not sufficiently aligned. In good consultation, the parties have therefore agreed on a leadership transition.

Pharming’s strategy, pipeline and commitment to patients remain unchanged. Focus remains on executing the strategic priorities and advancing the next phase of growth.

“On behalf of the Board, I would like to express our appreciation for Mr. Chouraqui’s contributions. We wish him well on his next endeavors,” said Richard Peters, Chairman of the Board of Directors of Pharming. “Our immediate priority is to ensure continuity across leadership, while maintaining focus on the continued execution of Pharming’s strategy and its commitment to patients.”

Fabrice Chouraqui added: “It has been a privilege to lead Pharming and to work alongside colleagues who are deeply committed to improving the lives of people with rare diseases. I have continually been inspired by the unwavering patient focus of our teams around the world and am deeply grateful for the passion and dedication they bring to our shared purpose every day. I leave with great confidence in their ability to continue expanding Pharming’s impact for patients and their families.”

To support an orderly transition process, Pharming and Mr. Chouraqui will not comment further beyond this announcement. 

About Pharming
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biotechnology company that develops and commercializes innovative medicines for people living with rare immune and genetic diseases.

We combine specialized scientific, medical, regulatory and commercial expertise to advance a focused portfolio of approved medicines and development programs that address significant unmet medical needs. Guided by insights from patients and the wider rare disease community, we are dedicated to delivering innovative therapies for some of the most challenging rare diseases.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:
Pharming
Saskia Mehring, Head of Corporate Communications
T: +31 6 28 32 60 41
E: media.relations@pharming.com

Forward-looking Statements
This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming’s preclinical studies and clinical trials of its product candidates, Pharming’s clinical and commercial prospects, and Pharming’s expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming’s clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming’s 2025 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming’s actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.

Inside Information
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Attachment

• Pharming announces CEO transition_EN_29SEP2026

Leiden, the Netherlands, September 29, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Mr. Chouraqui will step down as Chief Executive Officer and Executive Director, with immediate effect.

To ensure continuity of leadership, the Board of Directors has appointed Mrs. Leverne Marsh, Chief Commercial Officer, and Mr. Kenneth Lynard, Chief Financial Officer, as Interim Co-CEOs, effective immediately. Mrs. Marsh will lead the patient-focused operations while Mr. Lynard will lead the global corporate functions. The Board has started a formal search for a permanent successor.

Following discussions about the execution of Pharming’s strategic priorities for the next phase of the company, the Board of Directors and Mr. Chouraqui have concluded that their views on how to advance the company’s strategy are not sufficiently aligned. In good consultation, the parties have therefore agreed on a leadership transition.

Pharming’s strategy, pipeline and commitment to patients remain unchanged. Focus remains on executing the strategic priorities and advancing the next phase of growth.

“On behalf of the Board, I would like to express our appreciation for Mr. Chouraqui’s contributions. We wish him well on his next endeavors,” said Richard Peters, Chairman of the Board of Directors of Pharming. “Our immediate priority is to ensure continuity across leadership, while maintaining focus on the continued execution of Pharming’s strategy and its commitment to patients.”

Fabrice Chouraqui added: “It has been a privilege to lead Pharming and to work alongside colleagues who are deeply committed to improving the lives of people with rare diseases. I have continually been inspired by the unwavering patient focus of our teams around the world and am deeply grateful for the passion and dedication they bring to our shared purpose every day. I leave with great confidence in their ability to continue expanding Pharming’s impact for patients and their families.”

To support an orderly transition process, Pharming and Mr. Chouraqui will not comment further beyond this announcement. 

About Pharming
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biotechnology company that develops and commercializes innovative medicines for people living with rare immune and genetic diseases.

We combine specialized scientific, medical, regulatory and commercial expertise to advance a focused portfolio of approved medicines and development programs that address significant unmet medical needs. Guided by insights from patients and the wider rare disease community, we are dedicated to delivering innovative therapies for some of the most challenging rare diseases.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:
Pharming
Saskia Mehring, Head of Corporate Communications
T: +31 6 28 32 60 41
E: media.relations@pharming.com

Forward-looking Statements
This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming’s preclinical studies and clinical trials of its product candidates, Pharming’s clinical and commercial prospects, and Pharming’s expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming’s clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming’s 2025 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming’s actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.

Inside Information
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Attachment

• Pharming announces CEO transition_EN_29SEP2026

2027-2029 Strategy:

Arcadis’ Reset: Focused Growth, Sustainable Value

• Arcadis’ Reset: Focused Growth, Sustainable Value strategy is based on three value creation principles: Focus on Strengths, Simplify around Clients and Drive Performance Culture; all enabled by AI and digital innovation.
• Divestment of the majority of the architecture business and China operations to accelerate value creation, expected to increase the operating EBITDA margin by ~100 basis points¹⁾.
• Reduction of ~1,000 FTEs as part of overhead rightsizing targeted in 2027, with continued hiring in growth areas.
• 2027–2029 financial targets:
  • Mid-single-digit organic net revenue growth;
  • Mid- to high-teens operating EBITDA margin;
  • Dividend payout ratio of 30–40% of net income from operations;
  • Net debt / operating EBITDA of 1.5–2.5x.
• 2026 Financial guidance reaffirmed: low-single-digit organic net revenue growth, operating EBITA margin of 11.7–12.0%, equivalent to an operating EBITDA margin of 14.3–14.6%.
• Non-financial targets set for 2027-2029 include: client satisfaction, Employee Net Promotor Score, safety improvement, and quantified material impact on sustainability through the Future IMPACT+ framework by 2035.

Amsterdam, 29 September 2026: Arcadis (EURONEXT: ARCAD), the leading global provider of data-driven sustainable design, engineering and consultancy solutions for natural and built assets, is hosting its Capital Markets Day in Amsterdam today to present its 2027–2029 strategy.

Heather Polinsky, Chief Executive Officer, said: “Arcadis’ Reset: Focused Growth, Sustainable Value sharpens our focus on the markets where demand is strongest, and our competitive differentiation is clear. Our people and our culture are what makes this possible, and our work addressing the world’s most complex infrastructure and environmental challenges is what makes it matter. We will invest in our Core and Accelerate industries, apply rigorous performance discipline to Optimize businesses, simplify the organization around clients and strengthen accountability. Combined with our leading market positions, specialist expertise and trusted client relationships, these actions are designed to translate our strategic strengths into stronger growth, higher margins and cash generation. We are building a more focused, higher-performing Arcadis that delivers sustainable value for shareholders, our people and our clients.”

Simon Crowe, Chief Financial Officer, said: “The financial rationale is compelling: a more focused portfolio, a structurally lower cost base and disciplined capital allocation will support higher margins, stronger cash generation and sustainable shareholder returns. The announced divestments are expected to increase the operating EBITDA margin by ~100 basis points¹⁾. Beyond this, we will improve win rates, drive billability and apply more targeted sales incentives and differentiated pricing. With most of our key clients currently taking only one of our six services, the cross-selling opportunity is significant.

We will also pursue disciplined bolt-on M&A in our Core and Accelerate industries to build out leading positions and scale in high-growth markets. Together, these actions give us a clear and structured path to a mid-to-high teens operating EBITDA margin by 2029 and we will assess share buybacks from excess cash following each full-year result. With our capital-light model and strong cash-generation potential, we see a clear pathway to more than double EBITDA over time.”

ARCADIS’ RESET: FOCUSED GROWTH, SUSTAINABLE VALUE

The strategy is built on three value-creation priorities: focus on strengths, simplify around clients and drive a performance culture, underpinned by AI and digital innovation.

FOCUS ON STRENGTHS

Arcadis is actively changing its portfolio, concentrating investment in the sectors and growth markets where its expertise is most recognized by clients and where structural demand is strongest.

1. Core
   • Where Arcadis holds strong leading positions in structurally growing markets
   • Includes industries Transportation and Energy & Water, 53% of net revenues¹⁾
   • Organic net revenue growth profile of mid to high single digit for Transportation, high single digit for Energy & Water
2. Accelerate
   • Where Arcadis is scaling rapidly in high-growth sectors, including data centers, life sciences, and semiconductors
   • Includes industries Industrial Manufacturing & Technology, 21% of net revenues
   • Organic net revenue growth profile of mid to high single digit
3. Optimize
   • Where Arcadis is applying strict margin discipline and divesting non-core assets, including the majority of the Architecture business and China operations
   • Includes Real Estate & Development industry, 26% of net revenues        

Arcadis expects the share of Core and Accelerate industries to grow from 74%¹⁾ to 85% of Total Net Revenues by 2029, improving the overall quality and profitability of the business.

Environmental services, a leading business representing approximately 20% of net revenues built over 138 years of industry leadership, will be scaled by embedding across all four industries.

SIMPLIFY AROUND CLIENTS

Arcadis is replacing its Global Business Area structure with a model in which profit and loss accountability follows the client, not the person. Account teams will bring together sales and delivery under one accountable team per account, eliminating duplication, speeding up decision-making and enabling more consistent, end-to-end service. A single global services and delivery business, with real-time visibility of talent and skills across the organisation, replaces the current more fragmented model. Continued growth of Arcadis’ Global Excellence Centers will improve consistency, speed and cost efficiency. AI, automation and standardisation will release capacity for higher-value work.

DRIVE PERFORMANCE CULTURE

Arcadis’ people-first culture is embedded in its ownership model. Building on this principle, Arcadis is building a high-performance culture that is clearer and more focused on impact, through performance-linked incentives, clear ownership of client satisfaction, growth and margins. More than 200 leaders were already appointed in 2026 to create a simpler, flatter and more agile business. The Lovinklaan Foundation, Arcadis’ largest shareholder, reinvests dividends in knowledge exchange, innovation and professional development, giving Arcadians a long-term stake in the company’s success. Combined, this will make Arcadis’ performance culture a direct driver of growth, margin and client impact.

EMBED AI AND DIGITAL

Arcadis is embedding AI and digital directly into how it delivers projects, wins work and operates the business. This is already creating value for clients across sectors, improving productivity, quality and outcomes. Arcadis focuses on structured data, partnerships, in-house capability and disciplined scaling to ensure the best ideas reach clients consistently and globally. Its new partnership with Autodesk is one example of how Arcadis embeds AI directly into the workflows, combining technology with Arcadis’ own data, knowledge and engineering expertise. In addition we see strong AI implementation, resulting from working with Nomic, Arcadis’ AI partner purpose-built for engineering. More than 400 engineers across 17 countries now use over 700 engineer-built workflows to analyze drawings, specifications and process complex project information. Both examples highlight AI in action, creating value.

NON-FINANCIAL TARGETS

The strategy is also underpinned by non-financial commitments. Arcadis has set the following non-financial targets for the 2027-2029 cycle:

• Client satisfaction score of 85% or above by 2029;
• Employee Net Promoter Score in the top quartile of the professional services sector;
• 30% improvement in recordable safety incidents and proactive safety behaviours by 2029;
• €100 Billion of client project construction value assessed annually through its Future IMPACT+ sustainability framework by 2035.

  ¹⁾ Based on 2025 full year results 

END

ARCADIS INVESTOR RELATIONS
Christine Disch | +31 (0)615376020 | christine.disch@arcadis.com
Investor calendar: https://www.arcadis.com/en/investors/investor-calendar

CAPITAL MARKETS DAY WEBCAST
Today at 14:00 CET: Capital Markets Day 2026 | General | Arcadis

ABOUT ARCADIS
Arcadis is the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets. We are around 34,000 architects, data analysts, designers, engineers, project planners, water management and sustainability experts, all driven by our passion for improving quality of life. As part of our commitment to accelerating a planet positive future, we work with our clients to make sustainable project choices, combining digital and human innovation, and embracing future-focused skills across the environment, energy and water, buildings, transport, and infrastructure sectors. We operate in over 30 countries and reported €5 billion in gross revenues for 2025. www.arcadis.com

REGULATED INFORMATION
This press release contains information that qualifies or may qualify as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Attachment

• 2027-2029 Strategy Arcadis Reset Focused Growth, Sustainable Value

2027-2029 Strategy:

Arcadis’ Reset: Focused Growth, Sustainable Value

• Arcadis’ Reset: Focused Growth, Sustainable Value strategy is based on three value creation principles: Focus on Strengths, Simplify around Clients and Drive Performance Culture; all enabled by AI and digital innovation.
• Divestment of the majority of the architecture business and China operations to accelerate value creation, expected to increase the operating EBITDA margin by ~100 basis points¹⁾.
• Reduction of ~1,000 FTEs as part of overhead rightsizing targeted in 2027, with continued hiring in growth areas.
• 2027–2029 financial targets:
  • Mid-single-digit organic net revenue growth;
  • Mid- to high-teens operating EBITDA margin;
  • Dividend payout ratio of 30–40% of net income from operations;
  • Net debt / operating EBITDA of 1.5–2.5x.
• 2026 Financial guidance reaffirmed: low-single-digit organic net revenue growth, operating EBITA margin of 11.7–12.0%, equivalent to an operating EBITDA margin of 14.3–14.6%.
• Non-financial targets set for 2027-2029 include: client satisfaction, Employee Net Promotor Score, safety improvement, and quantified material impact on sustainability through the Future IMPACT+ framework by 2035.

Amsterdam, 29 September 2026: Arcadis (EURONEXT: ARCAD), the leading global provider of data-driven sustainable design, engineering and consultancy solutions for natural and built assets, is hosting its Capital Markets Day in Amsterdam today to present its 2027–2029 strategy.

Heather Polinsky, Chief Executive Officer, said: “Arcadis’ Reset: Focused Growth, Sustainable Value sharpens our focus on the markets where demand is strongest, and our competitive differentiation is clear. Our people and our culture are what makes this possible, and our work addressing the world’s most complex infrastructure and environmental challenges is what makes it matter. We will invest in our Core and Accelerate industries, apply rigorous performance discipline to Optimize businesses, simplify the organization around clients and strengthen accountability. Combined with our leading market positions, specialist expertise and trusted client relationships, these actions are designed to translate our strategic strengths into stronger growth, higher margins and cash generation. We are building a more focused, higher-performing Arcadis that delivers sustainable value for shareholders, our people and our clients.”

Simon Crowe, Chief Financial Officer, said: “The financial rationale is compelling: a more focused portfolio, a structurally lower cost base and disciplined capital allocation will support higher margins, stronger cash generation and sustainable shareholder returns. The announced divestments are expected to increase the operating EBITDA margin by ~100 basis points¹⁾. Beyond this, we will improve win rates, drive billability and apply more targeted sales incentives and differentiated pricing. With most of our key clients currently taking only one of our six services, the cross-selling opportunity is significant.

We will also pursue disciplined bolt-on M&A in our Core and Accelerate industries to build out leading positions and scale in high-growth markets. Together, these actions give us a clear and structured path to a mid-to-high teens operating EBITDA margin by 2029 and we will assess share buybacks from excess cash following each full-year result. With our capital-light model and strong cash-generation potential, we see a clear pathway to more than double EBITDA over time.”

ARCADIS’ RESET: FOCUSED GROWTH, SUSTAINABLE VALUE

The strategy is built on three value-creation priorities: focus on strengths, simplify around clients and drive a performance culture, underpinned by AI and digital innovation.

FOCUS ON STRENGTHS

Arcadis is actively changing its portfolio, concentrating investment in the sectors and growth markets where its expertise is most recognized by clients and where structural demand is strongest.

1. Core
   • Where Arcadis holds strong leading positions in structurally growing markets
   • Includes industries Transportation and Energy & Water, 53% of net revenues¹⁾
   • Organic net revenue growth profile of mid to high single digit for Transportation, high single digit for Energy & Water
2. Accelerate
   • Where Arcadis is scaling rapidly in high-growth sectors, including data centers, life sciences, and semiconductors
   • Includes industries Industrial Manufacturing & Technology, 21% of net revenues
   • Organic net revenue growth profile of mid to high single digit
3. Optimize
   • Where Arcadis is applying strict margin discipline and divesting non-core assets, including the majority of the Architecture business and China operations
   • Includes Real Estate & Development industry, 26% of net revenues        

Arcadis expects the share of Core and Accelerate industries to grow from 74%¹⁾ to 85% of Total Net Revenues by 2029, improving the overall quality and profitability of the business.

Environmental services, a leading business representing approximately 20% of net revenues built over 138 years of industry leadership, will be scaled by embedding across all four industries.

SIMPLIFY AROUND CLIENTS

Arcadis is replacing its Global Business Area structure with a model in which profit and loss accountability follows the client, not the person. Account teams will bring together sales and delivery under one accountable team per account, eliminating duplication, speeding up decision-making and enabling more consistent, end-to-end service. A single global services and delivery business, with real-time visibility of talent and skills across the organisation, replaces the current more fragmented model. Continued growth of Arcadis’ Global Excellence Centers will improve consistency, speed and cost efficiency. AI, automation and standardisation will release capacity for higher-value work.

DRIVE PERFORMANCE CULTURE

Arcadis’ people-first culture is embedded in its ownership model. Building on this principle, Arcadis is building a high-performance culture that is clearer and more focused on impact, through performance-linked incentives, clear ownership of client satisfaction, growth and margins. More than 200 leaders were already appointed in 2026 to create a simpler, flatter and more agile business. The Lovinklaan Foundation, Arcadis’ largest shareholder, reinvests dividends in knowledge exchange, innovation and professional development, giving Arcadians a long-term stake in the company’s success. Combined, this will make Arcadis’ performance culture a direct driver of growth, margin and client impact.

EMBED AI AND DIGITAL

Arcadis is embedding AI and digital directly into how it delivers projects, wins work and operates the business. This is already creating value for clients across sectors, improving productivity, quality and outcomes. Arcadis focuses on structured data, partnerships, in-house capability and disciplined scaling to ensure the best ideas reach clients consistently and globally. Its new partnership with Autodesk is one example of how Arcadis embeds AI directly into the workflows, combining technology with Arcadis’ own data, knowledge and engineering expertise. In addition we see strong AI implementation, resulting from working with Nomic, Arcadis’ AI partner purpose-built for engineering. More than 400 engineers across 17 countries now use over 700 engineer-built workflows to analyze drawings, specifications and process complex project information. Both examples highlight AI in action, creating value.

NON-FINANCIAL TARGETS

The strategy is also underpinned by non-financial commitments. Arcadis has set the following non-financial targets for the 2027-2029 cycle:

• Client satisfaction score of 85% or above by 2029;
• Employee Net Promoter Score in the top quartile of the professional services sector;
• 30% improvement in recordable safety incidents and proactive safety behaviours by 2029;
• €100 Billion of client project construction value assessed annually through its Future IMPACT+ sustainability framework by 2035.

  ¹⁾ Based on 2025 full year results 

END

ARCADIS INVESTOR RELATIONS
Christine Disch | +31 (0)615376020 | christine.disch@arcadis.com
Investor calendar: https://www.arcadis.com/en/investors/investor-calendar

CAPITAL MARKETS DAY WEBCAST
Today at 14:00 CET: Capital Markets Day 2026 | General | Arcadis

ABOUT ARCADIS
Arcadis is the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets. We are around 34,000 architects, data analysts, designers, engineers, project planners, water management and sustainability experts, all driven by our passion for improving quality of life. As part of our commitment to accelerating a planet positive future, we work with our clients to make sustainable project choices, combining digital and human innovation, and embracing future-focused skills across the environment, energy and water, buildings, transport, and infrastructure sectors. We operate in over 30 countries and reported €5 billion in gross revenues for 2025. www.arcadis.com

REGULATED INFORMATION
This press release contains information that qualifies or may qualify as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Attachment

• 2027-2029 Strategy Arcadis Reset Focused Growth, Sustainable Value

Louvain-La-Neuve, Belgium, September 29, 2026 at 7 a.m. CEST – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with the Istituti Fisioterapici Ospitalieri & Istituto Nazionale Tumori Regina Elena (IFO), to provide a turnkey proton therapy solution in Rome, Italy. The center will be the first gantry-based proton therapy system available in central and southern Italy.

Following a rigorous public tender process, IBA and its partners Cecchini SRL and Gowen SRL, construction companies and RTI (Temporary Grouping of Companies) members, have been selected by IFO to deliver a turnkey compact gantry-based Proteus^®ONE¹ system at the Istituti Fisioterapici Ospitalieri center in Rome. IFO will use proton therapy treatment modality for both pediatric and adult patients. As proton therapy is not currently available in central or southern Italy, this landmark project will bring the latest and most widely used gantry-based proton therapy technology with proven high clinical versatility to Italian patients. IFO expects to start treating patients in 2030.

The contract includes the supply of the latest-generation proton therapy system, Proteus^®ONE, design, build, installation, and a comprehensive training & education program as well as a one-year operation and maintenance agreement. As the market-leading compact proton therapy solution, Proteus^®ONE is designed to continuously evolve and integrate the latest technological advancements, enabling IBA users to benefit from cutting-edge innovation and adaptable capabilities.

Henri de Romrée, Deputy Chief Executive Officer of IBA, commented: “We are proud to partner with IFO on this landmark project, which will make gantry-based proton therapy available to patients in central and southern Italy for the first time. With Proteus^®ONE, IBA brings a proven, compact gantry solution designed to broaden access to advanced cancer care and support the treatment of a wide range of clinical indications. This collaboration reflects our shared commitment to bringing innovative, high-quality cancer treatments closer to patients.”

Giuseppe Navanteri, Chief Clinical Engineering and Technology officer of IFO, added: “We are pleased to work with IBA to bring proton therapy closer to patients in our region. We are convinced that choosing a gantry-based solution will provide the clinical versatility needed, enabling more patients to benefit from the advantages of proton therapy. This project represents an important step forward in expanding access to advanced cancer care in central and southern Italy.”

The typical end user price of a Proteus^®️ONE system with a multiyear maintenance contract ranges between €35 and €45 million.

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals, and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com.

About IFO

The Istituti Fisioterapici Ospitalieri (IFO) of Rome is one of Italy’s leading public research hospitals and comprises two Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS): the Regina Elena National Cancer Institute (IRE), dedicated to oncology, and the San Gallicano Dermatological Institute (ISG), specialized in dermatology. Founded in 1939, IFO combines patient care, clinical research, education, and innovation, serving as a national and international reference center for cancer treatment, dermatology, translational research, and precision medicine. Located in Rome, IFO is accredited by several international organizations and is recognized for excellence in multidisciplinary patient care, advanced therapies, and scientific research.

CONTACTS
Thomas Pevenage
Investor Relations
+32 10 475 890
investorrelations@iba-group.com

Nathalie van Ypersele
Head of Communication and Sustainability

Daniel Ernult
Corporate Communication Manager
+32 10 475 890
communication@iba-group.com

---

¹ Proteus^®ONE is a brand name of Proteus^®235

Attachment

• 260929-IBA-ProteusONE-Rome-EN